Good idea going to SBH site, however
I only found the following snips--I see
no indication at the SBH website that they
are advertising continued support. However,
that was said at the informed investors presentation.
Locilex has demonstrated effectiveness
against gram-positive, gram-negative and anaerobic
pathogens. It is currently under review by the U.S.
FDA for the topical treatment of infected diabetic
foot ulcers. Studies have shown that, applied topically,
Locilex is comparable to an orally administered quinolone
antibiotic
Locilex (pexiganan), a topical antibiotic and the first-ever antimicrobial peptide of animal origin, is currently under
review by the U.S. FDA for the topical treatment of infected
diabetic foot ulcers. A recent study suggests that Locilex,
which is in-licensed from Magainin Pharmaceuticals, is
effective against a broad spectrum of pathogens, including
gram-positive, gram-negative and anaerobic bacteria.
and a couple of pipeline graphics...
sb.com
sb.com
I interpret the recent weak stock price as a combination
of things:
1. misunderstanding that the FDA panel is not the final word
2. An unwillingness to invest in microcap biotech
3. A misunderstanding of Squalamine--I wonder if it is
often confused with that shark cartlidge cancer curing
scam--recently there have been reports in the media about
various cancer scams, and I saw one about folks buying ground
up shark cartiledge.
|
